New ZealandTuberculosis profile
Population  2015 4.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.01 (0.01–0.01) 0.22 (0.22–0.22)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0 (0–0.02)
Incidence  (includes HIV+TB) 0.34 (0.29–0.39) 7.4 (6.4–8.5)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.03 (0.03–0.04)
Incidence (MDR/RR-TB)** 0.01 (<0.01–0.019) 0.22 (0.04–0.42)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (<0.01–0.014) 0.15 (0.11–0.18) 0.15 (0.12–0.19)
Males 0.016 (0.011–0.022) 0.17 (0.13–0.2) 0.18 (0.14–0.22)
Total 0.025 (0.018–0.031) 0.31 (0.28–0.34) 0.34 (0.29–0.39)
TB case notifications, 2015  
Total cases notified 297
Total new and relapse 292
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 82%
          - % pulmonary 55%
          - % bacteriologically confirmed among pulmonary 89%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.03 (0.03–0.04)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 1 <1%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  6
(1–10)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.7–6.4) 20% (0.51–72)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 82% 296
Previously treated cases, excluding relapse, registered in 2014 33% 6
HIV-positive TB cases, all types, registered in 2014 100% 2
MDR/RR-TB cases started on second-line treatment in 2013 100% 3
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data